메뉴 건너뛰기




Volumn 17, Issue 4, 2017, Pages 387-394

Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review

Author keywords

atezolizumab; nivolumab; ocular toxicities; Pembrolizumab

Indexed keywords

DOCETAXEL; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 85015831479     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1080/14737140.2017.1296765     Document Type: Review
Times cited : (123)

References (83)
  • 1
    • 84933678156 scopus 로고    scopus 로고
    • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
    • Eggermont AM, Chiarion-Sileni V, Grob -J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071):a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–530.
    • (2015) Lancet Oncol , vol.16 , Issue.5 , pp. 522-530
    • Eggermont, A.M.1    Chiarion-Sileni, V.2    Grob, J.3
  • 2
    • 84961588720 scopus 로고    scopus 로고
    • Advances in cancer immunology and cancer immunotherapy
    • Voena C, Chiarle R., Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016;21(114):125–133.
    • (2016) Discov Med , vol.21 , Issue.114 , pp. 125-133
    • Voena, C.1    Chiarle, R.2
  • 3
    • 84946607195 scopus 로고    scopus 로고
    • Nivolumab versus everolimus in advanced renal-cell carcinoma
    • Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
    • (2015) N Engl J Med , vol.373 , Issue.19 , pp. 1803-1813
    • Motzer, R.J.1    Escudier, B.2    McDermott, D.F.3
  • 4
    • 84965149585 scopus 로고    scopus 로고
    • Immune checkpoint inhibitors in lung cancer: past, present and future
    • Seetharamu N, Budman DR, Sullivan KM. Immune checkpoint inhibitors in lung cancer:past, present and future. Future Oncol. 2016;12(9):1151–1163.
    • (2016) Future Oncol , vol.12 , Issue.9 , pp. 1151-1163
    • Seetharamu, N.1    Budman, D.R.2    Sullivan, K.M.3
  • 5
    • 84959869247 scopus 로고    scopus 로고
    • Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non- small cell lung cancer (NSCLC): a review on toxicity profile and its management
    • Sgambato A, Casaluce F, Sacco PC, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non- small cell lung cancer (NSCLC):a review on toxicity profile and its management. Curr Drug Saf. 2016;11(1):62–68.
    • (2016) Curr Drug Saf , vol.11 , Issue.1 , pp. 62-68
    • Sgambato, A.1    Casaluce, F.2    Sacco, P.C.3
  • 6
    • 84930912300 scopus 로고    scopus 로고
    • Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a ‘new frontier’?
    • Pilotto S, Kinspergher S, Peretti U, et al. Immune checkpoint inhibitors for non-small-cell lung cancer:does that represent a ‘new frontier’?. Anticancer Agents Med Chem. 2015;15(3):307–313.
    • (2015) Anticancer Agents Med Chem , vol.15 , Issue.3 , pp. 307-313
    • Pilotto, S.1    Kinspergher, S.2    Peretti, U.3
  • 7
    • 84879579673 scopus 로고    scopus 로고
    • At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
    • Intlekofer AM, Thompson CB. At the bench:preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.
    • (2013) J Leukoc Biol , vol.94 , Issue.1 , pp. 25-39
    • Intlekofer, A.M.1    Thompson, C.B.2
  • 8
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
    • (2010) N Engl J Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O’Day, S.J.2    McDermott, D.F.3
  • 9
    • 84929481480 scopus 로고    scopus 로고
    • Pembrolizumab for the treatment of non-small-cell lung cancer
    • Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
    • (2015) N Engl J Med , vol.372 , Issue.21 , pp. 2018-2028
    • Garon, E.B.1    Rizvi, N.A.2    Hui, R.3
  • 10
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
    • (2015) N Engl J Med , vol.373 , Issue.2 , pp. 123-135
    • Brahmer, J.1    Reckamp, K.L.2    Baas, P.3
  • 11
    • 84962038946 scopus 로고    scopus 로고
    • Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    • Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 2016;387(10030):1837–1846.
    • (2016) The Lancet
    • Fehrenbacher, L.1    Spira, A.2    Ballinger, M.3
  • 12
    • 84942236061 scopus 로고    scopus 로고
    • Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
    • Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors:a meta-analysis. Future Oncol. 2015;11(17):2471–2484.• This work evaluated the incidence and risk of various cutaneous toxicities among solid tumor patients treated with immune checkpoint inhibitors.
    • (2015) Future Oncol , pp. 2484
    • Abdel-Rahman, O.1    ElHalawani, H.2    Fouad, M.3
  • 13
    • 84942294585 scopus 로고    scopus 로고
    • Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
    • Abdel-Rahman O, ElHalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors:a meta-analysis. Expert Opin Drug Saf. 2015;14(10):1507–1518.• This work summarizes the incidence and risk of elevated transaminases among solid tumor patients treated with immune checkpoint inhibitors.
    • (2015) Expert Opin Drug Saf , vol.14 , Issue.10 , pp. 1507-1518
    • Abdel-Rahman, O.1    ElHalawani, H.2    Fouad, M.3
  • 14
    • 84961325991 scopus 로고    scopus 로고
    • Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
    • Abdel-Rahman O, ElHalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors:a meta-analysis. Future Oncol. 2016;12(3):413–425.• This work summarizes the incidence and risk of endocrine toxicities among solid tumor patients treated with immune checkpoint inhibitors.
    • (2016) Future Oncol , pp. 425
    • Abdel-Rahman, O.1    ElHalawani, H.2    Fouad, M.3
  • 15
    • 84948171577 scopus 로고    scopus 로고
    • Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
    • Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors:a meta-analysis. Immunotherapy. 2015;7(11):1213–1227.
    • (2015) Immunotherapy , vol.7 , Issue.11 , pp. 1213-1227
    • Abdel-Rahman, O.1    ElHalawani, H.2    Fouad, M.3
  • 16
    • 84973573023 scopus 로고    scopus 로고
    • Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
    • Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors:a meta-analysis. Ther Adv Respir Dis. 2016;10:183–193.
    • (2016) Ther Adv Respir Dis , vol.10 , pp. 183-193
    • Abdel-Rahman, O.1    Fouad, M.2
  • 17
    • 84991214698 scopus 로고    scopus 로고
    • Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    • Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-related death in cancer patients treated with immune checkpoint inhibitors:a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2016. Doi:10.1016/j.clon.2016.11.007.
    • (2016) Clin Oncol (R Coll Radiol)
    • Abdel-Rahman, O.1    Helbling, D.2    Schmidt, J.3
  • 18
    • 84968911282 scopus 로고    scopus 로고
    • A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
    • Abdel-Rahman O, Fouad M. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy. 2016;8(5):665–674.
    • (2016) Immunotherapy , vol.8 , Issue.5 , pp. 665-674
    • Abdel-Rahman, O.1    Fouad, M.2
  • 19
    • 84991214698 scopus 로고    scopus 로고
    • Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis
    • Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2016;28(10):e127–38.
    • (2016) Clin Oncol (R Coll Radiol) , vol.28 , Issue.10 , pp. e127-e138
    • Abdel-Rahman, O.1    Helbling, D.2    Schmidt, J.3
  • 20
    • 80052307183 scopus 로고    scopus 로고
    • Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]
    • Higgins JPT, Green S, (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from:www.cochrane-handbook.org.
    • (2011) The Cochrane Collaboration
    • Higgins, J.P.T.1    Green, S.2
  • 21
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
    • (1986) Control Clin Trials , vol.7 , Issue.3 , pp. 177-188
    • DerSimonian, R.1    Laird, N.2
  • 22
    • 0041876133 scopus 로고    scopus 로고
    • Measuring inconsistency in meta-analyses
    • Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ:Br Med J. 2003;327(7414):557.
    • (2003) BMJ: Br Med J , vol.327 , Issue.7414 , pp. 557
    • Higgins, J.P.1    Thompson, S.G.2    Deeks, J.J.3
  • 23
    • 84901641673 scopus 로고    scopus 로고
    • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
    • Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712.
    • (2014) Lancet Oncol , vol.15 , Issue.7 , pp. 700-712
    • Kwon, E.D.1    Drake, C.G.2    Scher, H.I.3
  • 24
    • 84929481481 scopus 로고    scopus 로고
    • Pembrolizumab versus ipilimumab in advanced melanoma
    • Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
    • (2015) N Engl J Med , vol.372 , Issue.26 , pp. 2521-2532
    • Robert, C.1    Schachter, J.2    Long, G.V.3
  • 25
    • 84923166043 scopus 로고    scopus 로고
    • Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma
    • Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712–720.
    • (2015) Clin Cancer Res , vol.21 , Issue.4 , pp. 712-720
    • Gibney, G.T.1    Kudchadkar, R.R.2    DeConti, R.C.3
  • 26
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
    • (2013) N Engl J Med , vol.369 , Issue.2 , pp. 122-133
    • Wolchok, J.D.1    Kluger, H.2    Callahan, M.K.3
  • 27
    • 85016509105 scopus 로고    scopus 로고
    • Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab
    • Weber J, Gibney G, Kudchadkar R, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4(4):345–353.
    • (2016) Cancer Immunol Res , vol.4 , Issue.4 , pp. 345-353
    • Weber, J.1    Gibney, G.2    Kudchadkar, R.3
  • 28
    • 84874605864 scopus 로고    scopus 로고
    • Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
    • Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616–622.
    • (2013) J Clin Oncol , vol.31 , Issue.5 , pp. 616-622
    • Ribas, A.1    Kefford, R.2    Marshall, M.A.3
  • 29
    • 84938205998 scopus 로고    scopus 로고
    • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
    • Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002):a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918.
    • (2015) Lancet Oncol , vol.16 , Issue.8 , pp. 908-918
    • Ribas, A.1    Puzanov, I.2    Dummer, R.3
  • 30
    • 84950117835 scopus 로고    scopus 로고
    • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    • Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial. Lancet (London, England). 2016;387(10027):1540–1550.
    • (2016) Lancet (London, England) , vol.387 , Issue.10027 , pp. 1540-1550
    • Herbst, R.S.1    Baas, P.2    Kim, D.W.3
  • 31
    • 84964341647 scopus 로고    scopus 로고
    • Association of pembrolizumab with tumor response and survival among patients with advanced melanoma
    • Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. Jama. 2016;315(15):1600–1609.
    • (2016) Jama , vol.315 , Issue.15 , pp. 1600-1609
    • Ribas, A.1    Hamid, O.2    Daud, A.3
  • 32
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
    • Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
    • (2013) N Engl J Med , vol.369 , Issue.2 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3
  • 33
    • 84908354848 scopus 로고    scopus 로고
    • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
    • Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma:a randomised dose-comparison cohort of a phase 1 trial. The Lancet. 2014;384(9948):1109–1117.
    • (2014) The Lancet , vol.384 , Issue.9948 , pp. 1109-1117
    • Robert, C.1    Ribas, A.2    Wolchok, J.D.3
  • 34
    • 84971619894 scopus 로고    scopus 로고
    • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
    • Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–983.
    • (2016) Lancet Oncol , vol.17 , Issue.7 , pp. 976-983
    • Goldberg, S.B.1    Gettinger, S.N.2    Mahajan, A.3
  • 35
    • 84969988424 scopus 로고    scopus 로고
    • Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
    • Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012):an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965.
    • (2016) Lancet Oncol , vol.17 , Issue.7 , pp. 956-965
    • Seiwert, T.Y.1    Burtness, B.2    Mehra, R.3
  • 36
    • 84904024273 scopus 로고    scopus 로고
    • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    • Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
    • (2014) Clin Cancer Res , vol.20 , Issue.19 , pp. 5064-5074
    • Taube, J.M.1    Klein, A.2    Brahmer, J.R.3
  • 37
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
    • (2015) N Engl J Med , vol.373 , Issue.17 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3
  • 38
    • 84951126341 scopus 로고    scopus 로고
    • Safety and antitumor activity of anti–pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer
    • Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti–pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022.
    • (2015) J Clin Oncol , vol.33 , Issue.34 , pp. 4015-4022
    • Hamanishi, J.1    Mandai, M.2    Ikeda, T.3
  • 39
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England J Med. 2015;373(1):23–34.
    • (2015) New England J Med , vol.373 , Issue.1 , pp. 23-34
    • Larkin, J.1    Chiarion-Sileni, V.2    Gonzalez, R.3
  • 41
    • 84929481482 scopus 로고    scopus 로고
    • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
    • Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017.
    • (2015) N Engl J Med , vol.372 , Issue.21 , pp. 2006-2017
    • Postow, M.A.1    Chesney, J.2    Pavlick, A.C.3
  • 42
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
    • Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
    • (2015) Lancet Oncol , vol.16 , Issue.4 , pp. 375-384
    • Weber, J.S.1    D’Angelo, S.P.2    Minor, D.3
  • 43
    • 84929361060 scopus 로고    scopus 로고
    • Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab
    • McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–2020.
    • (2015) J Clin Oncol , vol.33 , Issue.18 , pp. 2013-2020
    • McDermott, D.F.1    Drake, C.G.2    Sznol, M.3
  • 44
    • 84924901863 scopus 로고    scopus 로고
    • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
    • Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–265.
    • (2015) Lancet Oncol , vol.16 , Issue.3 , pp. 257-265
    • Rizvi, N.A.1    Mazieres, J.2    Planchard, D.3
  • 45
    • 84925222119 scopus 로고    scopus 로고
    • Nivolumab in previously untreated melanoma without BRAF mutation
    • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
    • (2015) N Engl J Med , vol.372 , Issue.4 , pp. 320-330
    • Robert, C.1    Long, G.V.2    Brady, B.3
  • 46
    • 84898973055 scopus 로고    scopus 로고
    • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    • Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
    • (2014) J Clin Oncol , vol.32 , Issue.10 , pp. 1020-1030
    • Topalian, S.L.1    Sznol, M.2    McDermott, D.F.3
  • 47
    • 84936937852 scopus 로고    scopus 로고
    • A phase 2 study of tremelimumab in patients with advanced uveal melanoma
    • Joshua AM, Monzon JG, Mihalcioiu C, et al. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015;25(4):342–347.
    • (2015) Melanoma Res , vol.25 , Issue.4 , pp. 342-347
    • Joshua, A.M.1    Monzon, J.G.2    Mihalcioiu, C.3
  • 48
    • 84926418972 scopus 로고    scopus 로고
    • Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
    • Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma:an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301–309.
    • (2015) Lancet Respir Med , vol.3 , Issue.4 , pp. 301-309
    • Calabrò, L.1    Morra, A.2    Fonsatti, E.3
  • 49
    • 84879141840 scopus 로고    scopus 로고
    • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    • Sangro B, Gomez-Martin C, De La Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88.
    • (2013) J Hepatol , vol.59 , Issue.1 , pp. 81-88
    • Sangro, B.1    Gomez-Martin, C.2    De La Mata, M.3
  • 50
    • 77955292303 scopus 로고    scopus 로고
    • Phase II study of the anti-cytotoxic t-lymphocyte–associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer
    • Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic t-lymphocyte–associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28(21):3485–3490.
    • (2010) J Clin Oncol , vol.28 , Issue.21 , pp. 3485-3490
    • Chung, K.Y.1    Gore, I.2    Fong, L.3
  • 51
    • 84959577118 scopus 로고    scopus 로고
    • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
    • Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm, multicentre, phase 2 trial. The Lancet. 2016;387(10031):1909–1920.
    • (2016) The Lancet , vol.387 , Issue.10031 , pp. 1909-1920
    • Rosenberg, J.E.1    Hoffman-Censits, J.2    Powles, T.3
  • 52
    • 84944718150 scopus 로고    scopus 로고
    • Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
    • Yamazaki N, Kiyohara Y, Uhara H, et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol. 2015;76(5):997–1004.
    • (2015) Cancer Chemother Pharmacol , vol.76 , Issue.5 , pp. 997-1004
    • Yamazaki, N.1    Kiyohara, Y.2    Uhara, H.3
  • 53
    • 84944896352 scopus 로고    scopus 로고
    • Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
    • Yamazaki N, Uhara H, Fukushima S, et al. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. Cancer Chemother Pharmacol. 2015;76(5):969–975.
    • (2015) Cancer Chemother Pharmacol , vol.76 , Issue.5 , pp. 969-975
    • Yamazaki, N.1    Uhara, H.2    Fukushima, S.3
  • 54
    • 84924543977 scopus 로고    scopus 로고
    • Phase II decog-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
    • Zimmer L, Vaubel J, Mohr P, et al. Phase II decog-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One. 2015;10(3):e0118564.
    • (2015) PLoS One , vol.10 , Issue.3 , pp. e0118564
    • Zimmer, L.1    Vaubel, J.2    Mohr, P.3
  • 55
    • 84908664534 scopus 로고    scopus 로고
    • Sargramostim plus ipilimumab vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial
    • Hodi FS, Lee S, McDermott DF, et al. Sargramostim plus ipilimumab vs ipilimumab alone for treatment of metastatic melanoma:a randomized clinical trial. JAMA. 2014;312(17):1744–1753.
    • (2014) JAMA , vol.312 , Issue.17 , pp. 1744-1753
    • Hodi, F.S.1    Lee, S.2    McDermott, D.F.3
  • 56
    • 84964313298 scopus 로고    scopus 로고
    • Bevacizumab plus ipilimumab in patients with metastatic melanoma
    • Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632–642.
    • (2014) Cancer Immunol Res , vol.2 , Issue.7 , pp. 632-642
    • Hodi, F.S.1    Lawrence, D.2    Lezcano, C.3
  • 57
    • 84896489380 scopus 로고    scopus 로고
    • A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    • Jochems C, Tucker JA, Tsang K-Y, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients:immune correlates. Ancer Immunol Immunother. 2014;63(4):407–418.
    • (2014) Ancer Immunol Immunother , vol.63 , Issue.4 , pp. 407-418
    • Jochems, C.1    Tucker, J.A.2    Tsang, K.-Y.3
  • 58
    • 84863911486 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
    • Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer:results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046–2054.
    • (2012) J Clin Oncol , vol.30 , Issue.17 , pp. 2046-2054
    • Lynch, T.J.1    Bondarenko, I.2    Luft, A.3
  • 59
    • 84871532643 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    • Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer:results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83.
    • (2013) Ann Oncol , vol.24 , Issue.1 , pp. 75-83
    • Reck, M.1    Bondarenko, I.2    Luft, A.3
  • 60
    • 84860446616 scopus 로고    scopus 로고
    • Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
    • Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases:an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–465.
    • (2012) Lancet Oncol , vol.13 , Issue.5 , pp. 459-465
    • Margolin, K.1    Ernstoff, M.S.2    Hamid, O.3
  • 61
    • 84860455345 scopus 로고    scopus 로고
    • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    • Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer:a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501–508.
    • (2012) Lancet Oncol , vol.13 , Issue.5 , pp. 501-508
    • Madan, R.A.1    Mohebtash, M.2    Arlen, P.M.3
  • 62
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 63
    • 77958050577 scopus 로고    scopus 로고
    • Phase 2 trial of single agent ipilimumab (anti-ctla-4) for locally advanced or metastatic pancreatic adenocarcinoma
    • Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-ctla-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–833.
    • (2010) J Immunother , vol.33 , Issue.8 , pp. 828-833
    • Royal, R.E.1    Levy, C.2    Turner, K.3
  • 64
    • 84963506978 scopus 로고    scopus 로고
    • Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report
    • Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis:case report. Can J Ophthalmol. 2016;51(1):e4–e6.
    • (2016) Can J Ophthalmol , vol.51 , Issue.1 , pp. e4-e6
    • Basilious, A.1    Lloyd, J.C.2
  • 66
    • 84964389238 scopus 로고    scopus 로고
    • Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
    • Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–225.
    • (2016) Eur J Cancer , vol.60 , pp. 210-225
    • Zimmer, L.1    Goldinger, S.M.2    Hofmann, L.3
  • 67
    • 84971222304 scopus 로고    scopus 로고
    • Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
    • Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect. 2016;6:14.
    • (2016) J Ophthalmic Inflamm Infect , vol.6 , pp. 14
    • Hahn, L.1    Pepple, K.L.2
  • 68
    • 84967153386 scopus 로고    scopus 로고
    • Intraocular inflammation associated with new therapies for cutaneous melanoma–case series and review
    • Fierz FC, Meier F, Chaloupka K, et al. Intraocular inflammation associated with new therapies for cutaneous melanoma–case series and review. Klin Monatsbl Augenheilkd. 2016;233(04):540–544.
    • (2016) Klin Monatsbl Augenheilkd , vol.233 , Issue.4 , pp. 540-544
    • Fierz, F.C.1    Meier, F.2    Chaloupka, K.3
  • 69
    • 84995743532 scopus 로고    scopus 로고
    • A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma
    • Hanna KS. A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy. 2016;36:e183-e188.
    • (2016) Pharmacotherapy , vol.36 , pp. e183-e188
    • Hanna, K.S.1
  • 70
    • 85015859208 scopus 로고    scopus 로고
    • Pembrolizumab administration associated with posterior uveitis
    • Aaberg MT, Aaberg TM, Jr. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep. 2016. [Epub ahead of print].
    • (2016) Retin Cases Brief Rep
    • Aaberg, M.T.1    Aaberg, T.M.2
  • 71
    • 84988428989 scopus 로고    scopus 로고
    • Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient
    • Arai T, Harada K, Usui Y, et al. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol. 2016 doi:10.1111/1346-8138.13612. [Epub ahead of print]
    • (2016) J Dermatol
    • Arai, T.1    Harada, K.2    Usui, Y.3
  • 72
    • 85043524023 scopus 로고    scopus 로고
    • Bilateral anterior uveitis associated with nivolumab therapy
    • Karlin J, Gentzler R, Golen J. Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm. 2016;1–3. [Epub ahead of print].
    • (2016) Ocul Immunol Inflamm , pp. 1-3
    • Karlin, J.1    Gentzler, R.2    Golen, J.3
  • 73
    • 84956836603 scopus 로고    scopus 로고
    • Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment
    • De Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheum (Hoboken, NJ). 2016;68(2):556–557.
    • (2016) Arthritis Rheum (Hoboken, NJ) , vol.68 , Issue.2 , pp. 556-557
    • De Velasco, G.1    Bermas, B.2    Choueiri, T.K.3
  • 74
    • 84922976477 scopus 로고    scopus 로고
    • New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
    • Miserocchi E, Cimminiello C, Mazzola M, et al. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol. 2015;50(1):e2–4.
    • (2015) Can J Ophthalmol , vol.50 , Issue.1 , pp. e2-e4
    • Miserocchi, E.1    Cimminiello, C.2    Mazzola, M.3
  • 75
    • 84906276850 scopus 로고    scopus 로고
    • Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash
    • Nallapaneni NN, Mourya R, Bhatt VR, et al. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw. 2014;12(8):1077–1081.
    • (2014) J Natl Compr Canc Netw , vol.12 , Issue.8 , pp. 1077-1081
    • Nallapaneni, N.N.1    Mourya, R.2    Bhatt, V.R.3
  • 76
    • 84997235698 scopus 로고    scopus 로고
    • Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab
    • Roberts P, Fishman GA, Joshi K, et al. Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol. 2016;134(10):1184–1188.
    • (2016) JAMA Ophthalmol , vol.134 , Issue.10 , pp. 1184-1188
    • Roberts, P.1    Fishman, G.A.2    Joshi, K.3
  • 77
    • 85015891770 scopus 로고    scopus 로고
    • Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients
    • Nguyen BH, Kuo J, Budiman A, et al. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2016. [Epub ahead of print].
    • (2016) Melanoma Res
    • Nguyen, B.H.1    Kuo, J.2    Budiman, A.3
  • 78
    • 84940182635 scopus 로고    scopus 로고
    • Ipilimumab-induced ocular and orbital inflammation–a case series and review of the literature
    • Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumab-induced ocular and orbital inflammation–a case series and review of the literature. Ocul Immunol Inflamm. 2016;24(2):140–146.
    • (2016) Ocul Immunol Inflamm , vol.24 , Issue.2 , pp. 140-146
    • Papavasileiou, E.1    Prasad, S.2    Freitag, S.K.3
  • 79
    • 84864052441 scopus 로고    scopus 로고
    • Management of immune-related adverse events and kinetics of response with ipilimumab
    • Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–2697.
    • (2012) J Clin Oncol , vol.30 , Issue.21 , pp. 2691-2697
    • Weber, J.S.1    Kähler, K.C.2    Hauschild, A.3
  • 80
    • 84959082340 scopus 로고    scopus 로고
    • Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation
    • Nguyen AT, Elia M, Materin MA, et al. Cyclosporine for dry eye associated with nivolumab:a case progressing to corneal perforation. Cornea. 2016;35(3):399–401.
    • (2016) Cornea , vol.35 , Issue.3 , pp. 399-401
    • Nguyen, A.T.1    Elia, M.2    Materin, M.A.3
  • 81
    • 84964703568 scopus 로고    scopus 로고
    • Ocular and orbital side-effects of checkpoint inhibitors: a review article
    • Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors:a review article. Curr Opin Oncol. 2016;28(4):288–294.
    • (2016) Curr Opin Oncol , vol.28 , Issue.4 , pp. 288-294
    • Antoun, J.1    Titah, C.2    Cochereau, I.3
  • 82
    • 84974678928 scopus 로고    scopus 로고
    • Immune check point inhibitors combination in melanoma: worth the toxicity?
    • Orloff M, Weight R, Valsecchi ME, et al. Immune check point inhibitors combination in melanoma:worth the toxicity? Rev Recent Clin Trials. 2016;11(2):81–86.
    • (2016) Rev Recent Clin Trials , vol.11 , Issue.2 , pp. 81-86
    • Orloff, M.1    Weight, R.2    Valsecchi, M.E.3
  • 83
    • 84988672464 scopus 로고    scopus 로고
    • Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy?
    • Diem S, Keller F, Ruesch R, et al. Pembrolizumab-triggered uveitis:an additional surrogate marker for responders in melanoma immunotherapy? J Immunother. 2016;39(9):379–382.
    • (2016) J Immunother , vol.39 , Issue.9 , pp. 379-382
    • Diem, S.1    Keller, F.2    Ruesch, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.